We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+75.99%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$607M
Cap. Flow
+$235M
Cap. Flow %
13.41%
Top 10 Hldgs %
43.13%
Holding
124
New
28
Increased
25
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$34.5M
2
CYTK icon
Cytokinetics
CYTK
+$28M
3
VTYX
Ventyx Biosciences
VTYX
+$19.1M
4
ROIV icon
Roivant Sciences
ROIV
+$17.8M
5
FBRX icon
Forte Biosciences
FBRX
+$17.3M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$66.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$56.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$42.8M
4
MRUS
Merus
MRUS
+$26.9M
5
SLNO
Soleno Therapeutics
SLNO
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$183M 10.42%
+1,500,000
New +$172M
APGE icon
2
Apogee Therapeutics
APGE
$10.1B
$93.2M 5.31%
1,234,926
+61,500
+5% +$3.87M
INSM icon
3
Insmed
INSM
$23.5B
$78.3M 4.46%
450,000
– –
ABVX
4
Abivax
ABVX
$11.9B
$68.1M 3.88%
505,000
+145,000
+40% +$15.8M
IBB icon
5
CALL
iShares Biotechnology ETF
IBB
$9.23B
$67.5M 3.85%
+400,000
New +$65M
VTYX
6
DELISTED
Ventyx Biosciences
VTYX
$58.6M 3.34%
6,484,558
+2,560,143
+65% +$19.1M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.6B
$56M 3.19%
1,250,000
-150,000
-11% -$6.3M
PRAX icon
8
Praxis Precision Medicines
PRAX
$8.77B
$54.5M 3.11%
+185,000
New +$34.5M
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$50.8M 2.9%
800,000
+450,000
+129% +$28M
SYRE icon
10
Spyre Therapeutics
SYRE
$8.7B
$46.9M 2.67%
1,432,591
+13,292
+0.9% +$347K
WVE icon
11
Wave Life Sciences
WVE
$1.12B
$45.9M 2.62%
2,700,000
+600,000
+29% +$6.1M
AMGN icon
12
CALL
Amgen
AMGN
$198B
$44.2M 2.52%
+135,000
New +$42.8M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$37.3B
$43.7M 2.49%
1,400,000
– –
XLV icon
14
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$41.4B
$38.7M 2.21%
+250,000
New +$37.4M
ROIV icon
15
Roivant Sciences
ROIV
$24.8B
$36.9M 2.1%
1,700,000
+900,000
+113% +$17.8M
ACLX
16
DELISTED
Arcellx
ACLX
$34.1M 1.95%
523,725
+23,725
+5% +$1.89M
NUVL
17
DELISTED
Nuvalent
NUVL
$32.5M 1.85%
322,633
-61,784
-16% -$6.09M
LXEO icon
18
Lexeo Therapeutics
LXEO
$368M
$31.8M 1.81%
3,200,000
-670,527
-17% -$6.12M
ALKS icon
19
Alkermes
ALKS
$8.79B
$28M 1.59%
1,000,000
-250,000
-20% -$7.49M
FBRX icon
20
Forte Biosciences
FBRX
$1B
$27M 1.54%
+989,490
New +$17.3M
TRVI icon
21
Trevi Therapeutics
TRVI
$2.71B
$26.9M 1.53%
2,150,172
-649,828
-23% -$7.51M
MLYS icon
22
Mineralys Therapeutics
MLYS
$2.39B
$26.5M 1.51%
730,000
-20,000
-3% -$802K
BBIO icon
23
BridgeBio Pharma
BBIO
$15.9B
$24.5M 1.39%
320,000
+255,000
+392% +$16.7M
ORKA
24
Oruka Therapeutics
ORKA
$5.59B
$24.3M 1.39%
802,342
-156,838
-16% -$4.37M
TERN
25
DELISTED
Terns Pharmaceuticals
TERN
$22.2M 1.27%
+550,000
New +$12.7M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Affinity Asset Advisors held 124 positions worth $1.76B, up 53% from $1.15B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $235M of net new capital in Q4 2025, opening 28 new positions and adding to 25 existing holdings. Its largest new stake was Praxis Precision Medicines: 185,000 shares worth $54.5M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $42.8M trimmed.

  • Affinity Asset Advisors's largest Q4 2025 buy was Praxis Precision Medicines: 185,000 shares worth $54.5M.
  • Affinity Asset Advisors added most to Cytokinetics in Q4 2025, an estimated $28M increase.
  • Affinity Asset Advisors's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $42.8M.
  • Affinity Asset Advisors fully exited Verona Pharma in Q4 2025, selling an estimated $66.7M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $1.76B portfolio in Q4 2025.
  • Affinity Asset Advisors opened 28 new positions and closed 29 in Q4 2025.
  • Affinity Asset Advisors's portfolio value rose 53% quarter-over-quarter to $1.76B.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.